Compounding this problem, trial sponsors ask the health institutions that host multicenter clinical trials not to independently evaluate the studies’ scientific merit or ethical soundness.
In this multicenter, double-blind trial, patients were randomized to oral ximelagatran 24 mg twice daily (n= 612) or placebo (n= 611) for 18 months.
One prospective, non-randomized, non-controlled, multicenter, clinical trial with two publications was retrieved.
Of the studies, 66 (73%) were single-center and 25 (27%) were multicenter studies.
A multicenter, randomized, controlled clinical trial was performed.
Such models can only be developed based on larger multicenter trials.
An additional 38 (24%) were cooperative group, multicenter oncology protocols.
In a refined 8-week multicenter replication, the results were similar.
